|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gut-liver axis signaling in portal hypertension显示文摘Portal hypertension(PHT)in advanced chronic liver disease(ACLD)results from increased intrahepatic resistance caused by pathologic changes of liver tissue composition(structural component)and intrahepatic vasoconstriction(functional component).PHT is an important driver of hepatic decompensation such as development of ascites or variceal bleeding.Dysbiosis and an impaired intestinal barrier in ACLD facilitate translocation of bacteria and pathogen-associated molecular patterns(PAMPs)that promote disease progression via immune system activation with subsequent induction of proinflammatory and profibrogenic pathways.Congestive portal venous blood flow represents a critical pathophysiological mechanism linking PHT to increased intestinal permeability:The intestinal barrier function is affected by impaired microcirculation,neoangiogenesis,and abnormal vascular and mucosal permeability.The close bidirectional relationship between the gut and the liver has been termed“gut-liver axis”.Treatment strategies targeting the gut-liver axis by modulation of microbiota composition and function,intestinal barrier integrity,as well as amelioration of liver fibrosis and PHT are supposed to exert beneficial effects.The activation of the farnesoid X receptor in the liver and the gut was associated with beneficial effects in animal experiments,however,further studies regarding efficacy and safety of pharmacological FXR modulation in patients with ACLD are needed.In this review,we summarize the clinical impact of PHT on the course of liver disease,discuss the underlying pathophysiological link of PHT to gut-liver axis signaling,and provide insight into molecular mechanisms that may represent novel therapeutic targets. | Benedikt Simbrunner Mattias Mandorfer Michael Trauner Thomas Reiberger | 2019 | World Journal of Gastroenterology2019，25，39： | 6 |
| 2 | Nonselective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis显示文摘 | T. Reiberger A. Ferlitsch B.A. Payer M. Mandorfer B.B. Heinisch H. Hayden F. Lammert M. Trauner M. Peck-Radosavljevic H. Vogelsang | 2012 | Journal of Hepatology2012，，： | 5 |
| 3 | Non-selective β Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis显示文摘 | Mattias Mandorfer Simona Bota Philipp Schwabl Theresa Bucsics Nikolaus Pfisterer Matthias Kruzik Michael Hagmann Alexander Blacky Arnulf Ferlitsch Wolfgang Sieghart Michael Trauner Markus Peck-Radosavljevic Thomas Reiberger | 2014 | Gastroenterology2014，，： | 3 |
| 4 | Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV–hepatitis C virus coinfected patients显示文摘 | Mattias Mandorfer Thomas Reiberger Berit A. Payer Arnulf Ferlitsch Florian Breitenecker Maximilian C. Aichelburg Barbara Obermayer-Pietsch Armin Rieger Michael Trauner Markus Peck-Radosavljevic | 2013 | AIDS2013，，2： | 1 |
| 5 | The influence of portal pressure on the discordance between absolute CD4 cell count and CD4 cell percentage in HIV/hepatitis C virus-coinfected patients显示文摘 | Mandorfer M Reiberger T Paver BA | 2013 | Clin Infect Dis2013，56，： | 1 |
| 6 | Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV–hepatitis C virus coinfected patients显示文摘 | Mattias Mandorfer Thomas Reiberger Berit A. Payer Arnulf Ferlitsch Florian Breitenecker Maximilian C. Aichelburg Barbara Obermayer-Pietsch Armin Rieger Michael Trauner Markus Peck-Radosavljevic | 2013 | AIDS2013，，2： | 1 |
| 7 | Interferon‐free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses显示文摘 | M. Mandorfer K. Kozbial C. Freissmuth P. Schwabl A. F. St?ttermayer T. Reiberger S. Beinhardt R. Schwarzer M. Trauner A. Ferlitsch H. Hofer M. Peck‐Radosavljevic P. Ferenci | 2015 | Aliment Pharmacol Ther2015，，6： | 1 |
| 8 | Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before,during,and after antiviral therapy with pegylated interferon plus ribavirin显示文摘 | Mandorfer M Payer B A Scheiner B | 2014 | Liver International2014，34，1： | 1 |
| 9 | Performance of 2-D Shear Wave Elastography in Liver Fibrosis Assessment Compared with Serologic Tests and Transient Elastography in Clinical Routine显示文摘 | Simona Bota Rafael Paternostro Alexandra Etschmaier Remy Schwarzer Petra Salzl Mattias Mandorfer Christian Kienbacher Monika Ferlitsch Thomas Reiberger Michael Trauner Markus Peck-Radosavljevic Arnulf Ferlitsch | 2015 | Ultrasound in Medicine & Biology2015，，9： | 1 |
| 10 | New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension显示文摘 | Philipp Schwabl Simona Bota Petra Salzl Mattias Mandorfer Berit A. Payer Arnulf Ferlitsch Judith Stift Friedrich Wrba Michael Trauner Markus Peck‐Radosavljevic Thomas Reiberger | 2015 | Liver Int2015，，2： | 1 |
| 11 | Ascites and complications: getting to the root of the trouble显示文摘After nearly a decade,the American Association for the Study of Liver Diseases has updated its guidance on the diagnosis,evaluation,and management of ascites and its complications(1).Ascites is the most common first hepatic decompensating event,thereby denoting the transition to from compensated advanced chronic liver disease(cACLD)to decompensated cirrhosis-(literally)a watershed moment in the natural history of liver disease(2). | Mattias Mandorfer Benedikt Simbrunner | 2023 | Hepatobiliary Surgery and Nutrition2023，12，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员